Literature DB >> 31712897

[Raynaud's phenomenon : Practical management].

C Drerup1, A Maier2, J Ehrchen3.   

Abstract

Raynaud's phenomenon (RP) is a frequent and painful vasospasm of small arteries localized in acral body regions (most frequently the fingers). The more frequent so-called primary RP is caused merely by a functional dysregulation of the tonus of vascular walls. In contrast, the rarer secondary RP is additionally associated with structural abnormalities of blood vessels. Knowledge of RP is important for rheumatologists because secondary RP can be associated with the presence or development of severe underlying diseases, especially with systemic sclerosis. Thus, the rheumatologist has to be aware of this condition. In this article the diagnostic procedures and the most important treatment approaches are summarized.

Entities:  

Keywords:  Acral circulatory disorder; Capillaroscopy; Cyanosis; Rheumatic diseases; Systemic sclerosis

Mesh:

Year:  2019        PMID: 31712897     DOI: 10.1007/s00393-019-00723-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  20 in total

1.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 2.  Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.

Authors:  Matthieu Roustit; Sophie Blaise; Yannick Allanore; Patrick H Carpentier; Evren Caglayan; Jean-Luc Cracowski
Journal:  Ann Rheum Dis       Date:  2013-02-20       Impact factor: 19.103

3.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

Review 4.  BSR and BHPR guideline for the treatment of systemic sclerosis.

Authors:  Christopher P Denton; Michael Hughes; Nataliya Gak; Josephine Vila; Maya H Buch; Kuntal Chakravarty; Kim Fligelstone; Luke L Gompels; Bridget Griffiths; Ariane L Herrick; Jay Pang; Louise Parker; Anthony Redmond; Jacob van Laar; Louise Warburton; Voon H Ong
Journal:  Rheumatology (Oxford)       Date:  2016-06-09       Impact factor: 7.580

5.  Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.

Authors:  R Scorza; M Caronni; B Mascagni; V Berruti; S Bazzi; E Micallef; G Arpaia; M Sardina; L Origgi; M Vanoli
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

6.  Update of EULAR recommendations for the treatment of systemic sclerosis.

Authors:  Otylia Kowal-Bielecka; Jaap Fransen; Jerome Avouac; Mike Becker; Agnieszka Kulak; Yannick Allanore; Oliver Distler; Philip Clements; Maurizio Cutolo; Laszlo Czirjak; Nemanja Damjanov; Francesco Del Galdo; Christopher P Denton; Jörg H W Distler; Ivan Foeldvari; Kim Figelstone; Marc Frerix; Daniel E Furst; Serena Guiducci; Nicolas Hunzelmann; Dinesh Khanna; Marco Matucci-Cerinic; Ariane L Herrick; Frank van den Hoogen; Jacob M van Laar; Gabriela Riemekasten; Richard Silver; Vanessa Smith; Alberto Sulli; Ingo Tarner; Alan Tyndall; Joep Welling; Frederic Wigley; Gabriele Valentini; Ulrich A Walker; Francesco Zulian; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2016-11-09       Impact factor: 19.103

7.  Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

Authors:  Martial Koenig; France Joyal; Marvin J Fritzler; André Roussin; Michal Abrahamowicz; Gilles Boire; Jean-Richard Goulet; Eric Rich; Tamara Grodzicky; Yves Raymond; Jean-Luc Senécal
Journal:  Arthritis Rheum       Date:  2008-12

Review 8.  Raynaud's phenomenon.

Authors:  Michael Hughes; Ariane L Herrick
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-05-11       Impact factor: 4.098

Review 9.  Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies.

Authors:  Rozeena Garner; Rakesh Kumari; Peter Lanyon; Michael Doherty; Weiya Zhang
Journal:  BMJ Open       Date:  2015-03-16       Impact factor: 2.692

Review 10.  Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms.

Authors:  Manal M Fardoun; Joseph Nassif; Khodr Issa; Elias Baydoun; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-11-16       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.